# DESTINY-Breast09 (NCT04784715)

> Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04784715
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Cancer; HER2-positive; Metastatic
- Interventions: Trastuzumab deruxtecan; Placebo; Taxane; Pertuzumab; Trastuzumab
- Enrollment: 1157
- Primary outcome: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 142
- X threads: 124
- Podcasts: 88
- X videos: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-breast09-nct04784715

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04784715", "email": "<work email>"}; the inbox owner confirms by the emailed link.